MedPath

Tioguanine

Generic Name
Tioguanine
Brand Names
Lanvis, Tabloid
Drug Type
Small Molecule
Chemical Formula
C5H5N5S
CAS Number
154-42-7
Unique Ingredient Identifier
WIX31ZPX66

Overview

An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

Indication

For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.

Associated Conditions

  • Acute Non-Lymphocytic Leukemia
  • Nonlymphocytic Acute myeloid leukemia

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
2024/08/01
NCT06533748
Phase 2
Recruiting
St. Jude Children's Research Hospital
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
2024/04/30
NCT06390319
Phase 2
Recruiting
St. Jude Children's Research Hospital
DEC-C and Thioguanine for R/R AML
2024/04/08
NCT06351306
Phase 2
Withdrawn
Columbia University
Ma-Spore ALL 2020 Study
2024/03/28
NCT06336395
Phase 2
Recruiting
National University Hospital, Singapore
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
2024/03/19
NCT06317662
Phase 2
Recruiting
National Cancer Institute (NCI)
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
2024/01/18
NCT06210750
Phase 2
Withdrawn
National Cancer Institute (NCI)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
2023/11/09
NCT06124157
Phase 3
Recruiting
National Cancer Institute (NCI)
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
2019/08/02
NCT04043494
Phase 3
Recruiting
University Hospital Muenster
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
2019/05/22
NCT03959085
Phase 3
Recruiting
Children's Oncology Group
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
2019/04/16
NCT03914625
Phase 3
Active, not recruiting
National Cancer Institute (NCI)

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
TABLOID
Woodward Pharma Services LLC
69784-630
ORAL
40 mg in 1 1
4/15/2022
TABLOID
Aspen Global Inc.
76388-880
ORAL
40 mg in 1 1
8/3/2022
TABLOID
Waylis Therapeutics LLC
80725-630
ORAL
40 mg in 1 1
5/15/2023

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Tioguanine Tablets
北京嘉林药业股份有限公司
国药准字H20003840
化学药品
片剂
12/11/2020
Tioguanine Tablets
广州白云山医药集团股份有限公司白云山制药总厂
国药准字H44023187
化学药品
片剂
4/9/2024

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
LANVIS tioguanine 40mg tablet bottle
11110
Aspen Pharmacare Australia Pty Ltd
Medicine
A
8/2/1991

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy